{
  "docId": "019de075-2dc4-7413-a6ea-ecd3ab0cc295",
  "docSlug": "e0f48061a961c5e04d59dc15b9a47e3c",
  "documentTitle": "MindMed | Investor Presentation Deck | 36 slides",
  "authorId": "mindmed",
  "authorName": "MindMed",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-06-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 3,
  "pageCount": 36,
  "prevPage": 2,
  "nextPage": 4,
  "slideType": "executive_summary",
  "function": "summarize",
  "density": "balanced",
  "nDataPoints": 0,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-2dc4-7413-a6ea-ecd3ab0cc295/3",
  "deckHref": "/decks/019de075-2dc4-7413-a6ea-ecd3ab0cc295",
  "deckJsonHref": "/decks/019de075-2dc4-7413-a6ea-ecd3ab0cc295.json",
  "deckAnchorHref": "/decks/019de075-2dc4-7413-a6ea-ecd3ab0cc295#slide-3",
  "components": [
    {
      "bbox": {
        "h": 0.15,
        "w": 0.9,
        "x": 0.05,
        "y": 0.00165
      },
      "kind": "callout",
      "text": "Our mission is to deliver on the therapeutic potential of psychedelics and other novel targets to treat brain health disorders",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "35932770-f838-4986-a7c4-8dff525d30cb",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.45,
        "w": 0.88,
        "x": 0.06,
        "y": 0.0036
      },
      "kind": "list",
      "text": "A leader in developing psychedelic product candidates to treat brain health disorders\nDiversified pipeline of clinical programs targeting significant unmet medical needs\nIP and R&D strategies intended to maximize market exclusivity and protection\nLeveraging decades of research on clinical and preclinical potential of product candidates\nExpertise in drug and digital medicine development and commercialization\nExpected cash runway through key clinical readouts and into first half of 2025",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "440859c1-c8bc-45dd-8477-437439f39635",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.29,
        "x": 0.058,
        "y": 0.05
      },
      "kind": "title",
      "text": "Business Highlights",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f55fb42e-c18f-451b-ad17-6c857cf23b73",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Executive summary",
      "slug": "executive-summary",
      "agent": null,
      "layer": "slide",
      "matchId": "070876bc-1b2d-4f3a-8b55-5befe68faf65",
      "evidence": "A leader in developing psychedelic product candidates to treat brain health disorders",
      "confidence": 0.9
    }
  ],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}